Cladribine for multiple sclerosis: review and current status (Q36307847)

13 August 2017

1 reference

title

Cladribine for multiple sclerosis: review and current status (English)

1 reference

13 August 2017

0 references

Jack C Sipe

1

1 reference

13 August 2017

publication date

1 November 2005

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

13 August 2017

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

721-727

1 reference

Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Cladribine (2-chlorodeoxyadenosine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

2-chloro-2'-deoxyadenosine in the treatment of Sjögren's syndrome-associated B cell lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

The clinical pharmacokinetics of cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

The treatment of chronic progressive multiple sclerosis with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Autoreactive CD8 T cells in multiple sclerosis: a new target for therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Infectious and immunosuppressive complications of purine analog therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Whole brain volume changes in patients with progressive MS treated with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

The effect of cladribine on T(1) 'black hole' changes in progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

A comparison of two neurologic scoring instruments for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.6.721

21 January 2018

Identifiers

DOI

10.1586/14737175.5.6.721

1 reference

13 August 2017

1 reference